Definitive Contract 75A50325C00019
Award Date
9/30/25
Potential Completion Date
9/29/30
Potential Value
$45M
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27701, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price purchase order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Glaxosmithkline, LLC, a foreign-owned pharmaceutical company, for the supply of RELENZA 5MG DISKHALER (NDC: 00173-0681-22). The contract has a potential value of $120,537.60 and a completion date of March 30, 2023. This award is not set-aside and appears to be part of the VA's broader efforts to procure pharmaceutical products and vaccines for its healthcare services....
This is a firm fixed price delivery order contract awarded by the Department of Homeland Security to Glaxosmithkline, LLC, a foreign-owned pharmaceutical company, to procure the antiviral medication Relenza. The contract has a potential value of $367,068.00 and does not have a set-aside designation. Glaxosmithkline has provided a range of pharmaceutical goods and services to various U.S. government agencies, including vaccines, antiviral medications, and other products to support disease...
This federal contract award to Glaxosmithkline, LLC, a pharmaceutical company, is for the drug RELENZA NDC # 00173-0681-22. The contract has a ceiling value of $249,900.00 and is a firm fixed price purchase order from the U.S. Department of Health and Human Services. The contract has an ultimate completion date of August 15, 2024 and was awarded on July 16, 2024. This award does not have a set-aside designation. Glaxosmithkline, a global pharmaceutical firm, frequently provides vaccines,...
This federal contract award to Glaxosmithkline, LLC (doing business as Glaxosmithkline) is for the purchase of 7,617 courses of the antiviral medication Zanamir (Relenza) at a firm fixed price of $17.37 per course, totaling $132,307.29. The award is from the Department of Homeland Security Countering Weapons of Mass Destruction program, with delivery required by October 31, 2018. The contract does not have a set-aside designation. Glaxosmithkline is a pharmaceutical company that provides a range...
This is a firm fixed-price delivery order awarded by the U.S. Department of Homeland Security, Countering Weapons of Mass Destruction office, to GlaxoSmithKline, LLC for the purchase of 30,800 courses of the antiviral medication Relenza at $21.72 per course, with a total ceiling value of $668,976. The order supports the Medical Countermeasures Program within the Occupational Health Branch. There was no set-aside designation for this award. GlaxoSmithKline is a pharmaceutical company that has...
This is a federal contract award to Glaxosmithkline, LLC by the U.S. Department of Homeland Security (DHS) for the acquisition of the antiviral medication Relenza to be included in the DHS antiviral stockpile. The contract has a ceiling value of $334,488 and is a firm fixed price delivery order. There is no set-aside designation for this award. Glaxosmithkline is a pharmaceutical company that provides a range of vaccines, antivirals, and other medical products to various U.S. government agencies...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Glaxosmithkline, LLC, doing business as Glaxosmithkline, a foreign-owned, for-profit pharmaceutical company. The contract is for the supply of zanamivir, an antiviral medication, with a potential value of $162,184.00. The contract does not have a set-aside designation and the place of performance is Research Triangle Park, North Carolina. Glaxosmithkline has provided a...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to GlaxoSmithKline, LLC to provide the antiviral medication zanamivir. The contract has a potential value of $289,864 and a completion date of February 19, 2019. GlaxoSmithKline, a foreign-owned for-profit pharmaceutical company, has provided a range of pharmaceutical goods and services to U.S. government agencies through various federal contract and grant awards, including...
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency Troop Support Medical to Glaxosmithkline, LLC, doing business as Glaxosmithkline, a foreign-owned for-profit pharmaceutical company. The $136,500.00 contract is for the supply of the antiviral medication zanamivir for inhalation. The contract has no set-aside designation and the period of performance is through April 14, 2023. Glaxosmithkline is a major supplier of pharmaceuticals, vaccines, and medical...
This federal contract award, with ID VA69D17C0092, is a definitive, firm fixed-price contract awarded by the Veterans Integrated Service Network 12 (VISN 12) of the U.S. Department of Veterans Affairs (VA) to GlaxoSmithKline, LLC (GSK) for the pharmaceutical product RELENZA NDC 00173-0681-22. The contract has a ceiling value of $3,906,776.00 and a completion date of April 30, 2017. GSK, a pharmaceutical company that provides vaccines, antivirals, and other products to U.S. government agencies,...